The IMI 2 Joint Undertaking aims to improve the drug development process by supporting more efficient research and development cooperation among academia, small and medium enterprises (SMEs) and the biopharmaceutical industry, in order to deliver better and safer medicines for patients.
In particular, it aims to address bottlenecks in areas of public health which are limiting the efficiency, effectiveness and quality of drug development activities needed to bring innovative medicines to the market.
The objectives are to:
- Increase the success rate in clinical trials of priority medicines identified by the World Health Organisation.
- Reduce the time to reach clinical proof of concept in medicine development, such as for immunological, respiratory, neurological and neurodegenerative diseases.
- Develop new therapies for diseases for which there is a high unmet need, such as Alzheimer’s disease and limited market incentives, such as antimicrobial resistance.
- Develop diagnostic and treatment biomarkers for diseases clearly linked to clinical relevance and approved by regulators.
- Reduce the failure rate of vaccine candidates in phase III clinical trials through new biomarkers for initial efficacy and safety checks.
- Improve the current drug development process by providing support for the development of tools, standards and approaches to assess efficacy, safety and quality of regulated health products.
Click here for more information